January 9, 2025

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Read more

Together,
we can reach higher ground

At Climb Bio, we believe elevating relationships leads to more meaningful insights, better answers, and ultimately, to more inspired medicines for patients living with immune-mediated diseases.

January 9, 2025

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Read more

Experienced team

At Climb Bio, our team has a knack for seeing what no one else sees—and a drive to achieve results no one expects.

Leadership Team Board of Directors

Elevating possibilities

Our pipeline is focused on immune-mediated diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of B-cell mediated diseases and CLYM116, an anti-APRIL antibody in IND-enabling studies for IgAN.

LEARN MORE ABOUT OUR SCIENCE
STAGE OF DEVELOPMENT
Indication(s)
Pre-Clinical
Phase 1
Phase 2
Phase 3

CANDIDATE

Budoprutug

Anti-CD19
Fc-engineered, monoclonal antibody

Indications

Membranous Nephropathy

Phase 1

Immune Thrombocytopenia*

Phase 1

Systemic Lupus Erythematosus

Phase 1

CANDIDATE

CLYM116**

Anti-APRIL

Indications

IgA Nephropathy

Pre-Clinical

*Subject to investigational new drug application clearance
**Worldwide rights outside of Greater China

Commitment to patients

We only have one life to live. At Climb, we all feel the urgency to give everyone living with an immune-mediated disease more quality time—and less time thinking of themselves as a patient.

Come climb with us

Here you’ll find good people. Smart people. Curious people. Our team has a diversified past, a singular focus on the now, and an unshakeable commitment to a better future.

OPEN POSITIONS:

There are currently no open positions.